IDEXX Laboratories, Inc. vs Wix.Com Ltd — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Wix.Com Ltd trades at $76.56 (market cap $3.11B). The key difference: IDEXX Laboratories, Inc. is far larger — about 13× Wix.Com Ltd's market cap, and Wix.Com Ltd is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Wix.Com Ltd for 62 Days on average.
| IDXX | WIX | |
|---|---|---|
Market Cap | $40.43B | $3.11B |
Volume | 692,164 | 809,286 |
Sector | Health | Technology |
52-Week High | $766.68 | $145.54 |
52-Week Low | $504.70 | $40.43 |
Typical Hold Time | 46 Days | 62 Days |
Enterprise Value | $41.32B | $4.19B |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
WIX stock trades at $74.13, up 1.59% today, with a neutral technical signal and bullish moving averages. Revenue grew to $1.99B in 2025, but net income margin is negative at -8.19%. The company faces a securities class action lawsuit, with multiple law firms announcing deadlines in late September 2026. Analyst consensus is a Buy with a $77.00 price target, though valuation ratios like P/E of 62.84 appear elevated.
The outlook is mixed: strong revenue growth and positive cash flow from operations support the bullish analyst stance, but legal risks and negative profitability margins pose significant headwinds. Upside depends on sustained earnings beats and resolution of litigation, while downside risks include prolonged negative margins and competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →